secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K/A
Filed at:   2022-08-29T23:59:59+00:00
Accession:  0001213900-22-051823
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea Therapeutics files Alpha-5 Integrin financials for acquisition closed June 21, 2022
--------------------------------------------------------------------------------

- Alpha-5 (preclinical-stage, ALS/neuroinflammatory mAbs) had no revenue and $1.7M net loss for FY 2021.
- Q1 2022 net loss was $447k; accumulated deficit reached $2.15M as of March 31, 2022.
- Total assets $200k, cash & equivalents $122k at March 31, 2022, down from $295k at year-end 2021.
- Acquisition closed June 21, 2022; one seller is Pasithea's Executive Chairman and Co-Founder.
- Pro forma adjustments deemed immaterial; Alpha-5 became a wholly owned subsidiary of Pasithea.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390022051823/0001213900-22-051823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390022051823/ea165047-8ka2_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-051823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer